1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Rare Diseases Clinical Research Network (RDCRN) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). The RDCRN is a program designed to advance medical research on rare diseases. It supports collaborative research among scientists and patient advocacy groups to study the natural history of rare diseases, develop new diagnostics and therapies, and conduct clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Consortia of clinical investigators and institutions with expertise in rare diseases, often including patient advocacy groups. Confirm the full requirements in the official notice before applying.
Rare Diseases Clinical Research Network (RDCRN) is funded by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). This grant supports exploratory and developmental research projects in areas relevant to the NIH mission, specifically those that do not involve clinical trials. NCATS participates in this program to foster research that accelerates translational science.
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). This program supports small research projects that can be carried out in a short period of time with limited resources. NCATS participates in this program to support innovative pilot projects and feasibility studies in translational science.
Rare Belonging® Grant Program is sponsored by Alexion Charitable Foundation. The Alexion Charitable Foundation's Rare Belonging® grant program supports programs and services that benefit individuals, caregivers, and families impacted by rare diseases, aligning with its mission to address health disparities within and among the rare disease community. Priorities include science-driven solutions, technology and innovation, patient supports, and research & policy focused on diagnostic pathways and systems improvements. The program specifically seeks to advance emotional well-being and educational opportunities, and provide relief for critical needs, especially for those living with or affected by a rare disease.
Alexion Charitable Foundation Grants is sponsored by Alexion Charitable Foundation. The Alexion Charitable Foundation (ACF) invests in projects to ensure that underserved communities have equitable pathways to the care, services, and resources they need to live healthier lives, with a focus on addressing health disparities within the rare disease community.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read article